1) Estudo mostrou que zoledronato anual preservou e aumentou a densidade óssea em homens usando agonista GnRH para câncer de próstata, reduzindo marcadores de turnover ósseo.
2) Estudo demonstrou que privação androgênica intermitente é viável para câncer de próstata localmente avançado/metastático, resultando em menos efeitos colaterais do que terapia contínua.
3) Estudo desenvolveu nomograma para prever resposta à radioterapia de salvamento após
5. Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized placebo-controlled trial. Abstract No: 4515. Authors: Michaelson MD, Lee H, Kaufman DS, Kantoff PW, Finkelstein J, Smith MR.
6.
7. Zoledronato anual Abs# 4515 Michaelson MD, et al. ASCO 2006. Abstract 4515. Homens com câncer de próstata não metastático em uso de agonista GnRH (N = 40) Zoledronato 4 mg IV , dose única Placebo Avaliação da densidade Óssea após 12 meses
8.
9.
10. Phase III intermittent MAB vs continuous MAB Abstract No: 4513 Authors: Calais Da Silva FM, Calais Da Silva F, Bono A, et al.
11. Privação Androgênica Intermitente vs Contínua Calais Da Silva FM, et al. ASCO 2006. Abstract 4513. Homens com doença localmente avançada ou metastatica, PSA > 4 ng/mL (N = 626) Privação Androgenica de indução * Privação Androgenica Contínua * (n = 312) Privação Androgenica intermitente * Tratmento reiniciado quando PSA ≥ 10 ng/mL com sintomas, PSA ≥ 20 ng/mL sem sintomas ou PSA ≥ 20% do valor de nadir (n = 314) 14 sem Se PSA < 4 ng/mL ou 80% abaixo do basal *Ciproterona 200 mg/dia por 2 sem, depois injeções mensais de inibidor LH-RH + ciproterona 200 mg/dia.
12.
13.
14.
15. Absolute PSA value after androgen deprivation (AD) is a strong predictor of survival in new metastatic (D2) prostate cancer (PCa): data from the Southwest Oncology Group Trial 9346 (INT-0162). Abstract No: 4517 Authors: Hussain M, Tangen CM, Schellhammer PF, et al.
16. SWOG 9346: Privação Androgênica Intermitente vs Contínua Hussain M, et al. ASCO 2006. Abstract 4517. Homens com diagnóstico de cancer de próstata metastático em início de tratamento, PSA ≥ 5 ng/mL (N = 1395) Terapia de Privação Androgênica Por 7 meses Continue terapia de privação androgênica Terapia androgênica intermitente Se PSA ≤ 4 ng/mL Mes 8
17.
18. Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival. Abstract No: 4568 Authors: Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, George DJ, Partin AW .
19.
20.
21. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Abstract No: 4514 Authors: Stephenson AJ, Pollack A, Kattan MW, Scardino PT, Post-Prostatectomy Radiotherapy Consortium .
29. Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). Abstract no. 4500. Authors: Milowsky MI, Galsky M, George DJ, et al.
30.
31. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). Abstract No: 4562. Authors: Mathew P, Thall PF, Johnson MM, et al.
32.
33. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (lx) or mitoxantrone/prednisone (MP). Abstract No: 4558 Authors: Lin AM, Rosenberg JE, Weinberg VK, et al.
34. Ixabepilone X mitoxantrona/pdn abs# 4558 Homens cancer de próstata resistente a hormonio e refratário a taxano (N = 82) Mitoxantrona 14mg/m2 IV 21 d (n=41) PDN 5mg 2x dia Ixabepilona 35mg/m2 IV 21d (n=41) Mitoxantrona 14mg/m2 IV 21 d (n=16) PDN 5mg 2x dia Ixabepilona 35mg/m2 IV 21d (n=29)
38. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. Abstract No: 4518 Authors: T. M. Beer, C. W. Ryan, P. M. Venner, D. P. Petrylak, G. Chatta, et al.
44. Terapias atuais em CCR avançado 1 JCO 2006;24:16-24; 2 ASCO 2005; Abs 4508; 3 JCO 1999;17:2039-2043; 4 JCO 2004;22:454-463; 5 JCO 2002;20:289-296; 6 JCO 2005;23:133-141; 7 ASCO 2005; Abs 4510 40% 3%** 169* 335 Motzer et al 1,2* Escudier et al 7 Sunitinib Trial 1,2* Sorafenib TARGET (PFS 24x12m)** 11% 23% 463 255 Motzer et al 5 McDermott et al 6 Interferon-alfa Interleucina-2 Alta Dose 113 251 N Terapia Convencional 1ª Linha 3% 4% Escudier et al 3 Motzer et al 4 Citoquinas Vários (dados históricos) Terapia de 2ª Linha Convencional TKIs 2ª Linha (aprovados FDA) Taxa de Resposta (%) Referência
45. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) Abstract No: LBA3 Author(s): R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. T. Kim, C. M. Baum, R. A. Figlin
46.
47. Tumores Malignos do Rim, Frequência e Oncogenes Lineham WM, et al. J Urol. 2003;170:2163-2172. BHD 5% Oncocitoma BHD 5% Cromofobo FH 10% Papilar tipo 2 Met 5% Papilar tipo 1 Oncogenes Frequência Relativa Tipo VHL 75% Carcinoma Células Claras
54. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) A bstract No: LBA4 Author(s): G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, T. O'Toole, Y. Park, L. Moore
55.
56. Overall Survival by Treatment Arm Arm 3: IFN + Temsirolimus Arm 2: Temsirolimus Arm 1: IFN Time from Randomization, Months Probability of Survival 0.6912 0.0069 Stratified Log-Rank p Arm 3 :Arm 1 Arm 2 :Arm 1 Comparisons 210 209 207 n TEMSR + IFN Arm 3 TEMSR Arm 2 IFN Arm 1 Parameter
57.
58.
59.
60.
61.
62. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. Abstract No: 4524 Author(s): T. Eisen, R. M. Bukowski, M. Staehler, C. Szczylik, S. Oudard, W. M. Stadler, B. Schwartz, R. Simantov, M. Shan, B. Escudier, For The Sorafenib TARGETs Clinical Trial Group
69. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. Abstract No: 4510 Author(s): D. F. Bajorin, C. R. Nichols, K. A. Margolin, J. Bacik, P. G. Richardson, N. J. Vogelzang, L. Einhorn, M. Mazumdar, G. J. Bosl, R. J. Motzer
70.
71. Single versus sequential high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ-cell tumors (GCT) Abstract No: 4511 Author(s): A. Lorch, O. Rick, J. T. Hartmann, C. Kollmannsberger, B. Metzner, I. Schmidt-Wolf, W. E. Berdel, R. Schirren, J. Beyer, C. Bokemeyer, for the German Testicular Cancer Study Group
72.
73. One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): [AUO]/German testicular cancer study group [GTCSG] Trial 01-94). Abstract No: 4512 Author(s): P. Albers, R. Siener, S. Krege, H. Schmelz, K. Dieckmann, A. Heidenreich, P. Kwasny, M. Pechoel, J. Lehmann, R. Fimmers, M. Hartmann
74.
75.
76. Otimização de Resultados (Craig Nichols, MD – discussão ) Observação RPLND + (PEBx2) PEBx1 Quimioterapia 52x3 38x2 + 14x3 174x1 Cirurgia 5-10 174+ 1-2 #Disrupted 52 174 174 Tempo disrupted 13 sem 6-19 sem 7 sem Tempo total # 676 sem 1606 sem 1218 sem Assume reinício de atividades 1 mês após quimioterapia e 6 semanas após cirurgia
80. Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis. Abstract No: 4519 Author(s): G. M. Mead, G. J. Rustin, S. P. Stenning, P. Vasey, N. Aass, R. Huddart, M. Sokal, S. Kirk
81.
82.
83.
84. A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. Abstract No: 4520 Author(s): R. Huddart, M. O'Doherty, A. Padhani, G. Rustin, G. Mead, J. K. Joffe, P. Vasey, S. Hain, S. J. Kirk, S. P. Stenning, L. National Cancer Research Center
85.
86. [18F]-FDG-PET in germ cell tumors following chemotherapy: Results of the German multicenter trial. Abstract No: 4521 Author(s): M. De Wit, M. Hartmann, W. Brenner, L. Weißbach, H. Amthauer, C. Franzius, S. Kliesch, S. Krege, R. Heicappell, R. Bares, C. Bokemeyer
87.
88.
89. Long-term non-cancer mortality among 39,657 one-year testicular cancer survivors (TCSs). Abstract No: 4508 Author(s): S. D. Fosså, J. Chen, G. M. Dores, K. A. McGlynn, S. J. Schonfeld, L. B. Travis, Nci Testicular Cancer Research Group
90.
91.
92.
93.
94.
95. Obrigado Carlos Frederico Pinto Oncologista Clínico Hospital Regional do Vale do Paraíba e Instituto de Oncologia do Vale [email_address]
97. Associations of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. Abstract No: 4516 Authors: Berthold DR, Pond G, De Wit R, Eisenberger MA, Tannock IF.
98.
Notas do Editor
BMD, bone mineral density; GnRH, gonadotropin-releasing hormone
Alk phos, alkaline phosphatase; BMD, bone mineral density; GnRH, gonadotropin-releasing hormone
PSA, prostate specific antigen
PSA, prostate specific antigen Androgen Deprivation Therapy consisted of cyproterone acetate 200 mg/day for 2 wks, then monthly depot injections of the luteinizing hormone-releasing hormone analogue decapeptyl + cyproterone acetate 200 mg/day.
PSA, prostate specific antigen
HR, hazard ratio; PSA, prostate specific antigen
BHD , Birt Hogg Dube; FH, fumarate hydratase; VHL, von Hippel-Lindau
Agree this is better. Also, I think the log–rank p values should be included here, since they represents survival comparisons over the entire study period, not just median survival. I would like Steve’s opinion on this.